Latest Content

Secukinumab becomes the only IL-17A inhibitor approved for this population and the first new mechanism in the indication in nearly a decade.

Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, supporting potential pediatric label expansion.

Vutrisiran kept a favorable safety profile in patients with transthyretin amyloidosis treated for up to 58 months, with AE rates comparable to placebo and no new safety concerns.

Legislation that passed the Senate will introduce reform in how pharmacy benefit managers are addressed by CMS starting in 2028.

Dr Wilfong's commentary will appear in the April issue of Evidence-Based Oncology.

Galleri trial data show liquid biopsy multicancer early detection tests may cut stage IV diagnoses, despite the missed primary end point.

Reproductive health conditions raise child desire but lower pregnancy intentions, spotlighting infertility gaps in women’s health and urging proactive counseling and coverage reform.

The website officially launched on February 5, introducing a key part of the Trump administration’s health care plan.

New studies link abortion bans to higher births and WIC demand and spotlight care-access gaps, cancer disparities, and value-based reforms shaping 2026.